Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07374848 | Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors | PHASE1 | RECRUITING | 180 | — | — | Mar 2, 2026 | Sep 1, 2029 | May 28, 2026 | 5 | United States |
Number of subjects with dose limiting toxicities (DLTs) through dose escalation only.
Number of subjects with treatment-emergent adverse effects through dose escalation and expansion.
Number of subjects with Serious Adverse Events through dose escalation and expansion.
Vitals will be measured in Riva Rocci (RR) in mmHG and Pulse in beats per minute
ECG will be measured in ECG intervals (QT and QTc with Fridericia correction, and PR), QRS duration, and heart rate will be tested and analyzed.
| Arm | Type | Description |
|---|---|---|
| ZL-6201 | EXPERIMENTAL | ZL-6201 as a single agent |
| Name | Type | Description |
|---|---|---|
| ZL-6201 | DRUG | ZL-6201 as a single-agent |
Inclusion Criteria: * Adult men and women ≥18 years of age at the time of signing the ICF with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy \> 3 months * Participants must have histologically confirmed and documented diagnosis of locally advanced u...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |